Search research articles
Contact Us
Filters
Showing results (101-110 of 107) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 107 results.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood
|
September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood
|
May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Nature Medicine
|
June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Haematologica
|
April 26, 2014
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia
Patrizia Noris, Nicole Schlegel, Catherine Klersy, et al.
Leukemia
|
April 11, 2019
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Maroulio Pertesi, Maxime Vallée, Xiaomu Wei, et al.
Journal of Clinical Immunology
|
August 12, 2019
A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency
Hélène Coignard-Biehler, Nizar Mahlaoui, Benoit Pilmis, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 107) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 107 results.
Blood
|
March 23, 2016
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau, Cyrille Hulin, Margaret Macro, et al.
Blood
|
September 26, 2018
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, et al.
Blood
|
May 5, 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, et al.
Nature Medicine
|
June 3, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jerome Lambert, et al.
Haematologica
|
April 26, 2014
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia
Patrizia Noris, Nicole Schlegel, Catherine Klersy, et al.
Leukemia
|
April 11, 2019
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
Maroulio Pertesi, Maxime Vallée, Xiaomu Wei, et al.
Journal of Clinical Immunology
|
August 12, 2019
A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency
Hélène Coignard-Biehler, Nizar Mahlaoui, Benoit Pilmis, et al.
Page
of 11